176 related articles for article (PubMed ID: 33217474)
1. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
[TBL] [Abstract][Full Text] [Related]
2. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
Gunawardana M; Remedios-Chan M; Miller CS; Fanter R; Yang F; Marzinke MA; Hendrix CW; Beliveau M; Moss JA; Smith TJ; Baum MM
Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
[TBL] [Abstract][Full Text] [Related]
4. The effect of depot medroxyprogesterone acetate on tenofovir alafenamide in rhesus macaques.
Daly MB; Sterling M; Holder A; Dinh C; Nishiura K; Khalil G; García-Lerma JG; Dobard C
Antiviral Res; 2021 Feb; 186():105001. PubMed ID: 33385420
[TBL] [Abstract][Full Text] [Related]
5. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Tissue Distribution Profile of Long Acting Tenofovir Alafenamide and Elvitegravir Loaded Nanoparticles in Humanized Mice Model.
Prathipati PK; Mandal S; Pon G; Vivekanandan R; Destache CJ
Pharm Res; 2017 Dec; 34(12):2749-2755. PubMed ID: 28905173
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
Makarova N; Singletary T; Peet MM; Mitchell J; Holder A; Dinh C; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Smith JM; Doncel GF
EBioMedicine; 2022 Dec; 86():104338. PubMed ID: 36343572
[TBL] [Abstract][Full Text] [Related]
8. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
Sizovs A; Pons-Faudoa FP; Malgir G; Shelton KA; Bushman LR; Chua CYX; Anderson PL; Nehete PN; Sastry KJ; Grattoni A
Int J Pharm; 2020 Sep; 587():119623. PubMed ID: 32663582
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
Gunawardana M; Remedios-Chan M; Sanchez D; Fanter R; Webster S; Webster P; Moss JA; Trinh M; Beliveau M; Ramirez CM; Marzinke MA; Kuo J; Gallay PA; Baum MM
Pharm Res; 2023 Jul; 40(7):1657-1672. PubMed ID: 36418671
[TBL] [Abstract][Full Text] [Related]
10. Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP).
Johnson LM; Krovi SA; Li L; Girouard N; Demkovich ZR; Myers D; Creelman B; van der Straten A
Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31277461
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
12. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
[TBL] [Abstract][Full Text] [Related]
13. Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.
Dumond JB; Greene SA; Prince HMA; Chen J; Maas BM; Sykes C; Schauer AP; Blake KH; Nelson JAE; Gay CL; Kashuba ADM; Cohen MS
Antivir Ther; 2019; 24(1):45-50. PubMed ID: 30375984
[TBL] [Abstract][Full Text] [Related]
14. A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
Schlesinger E; Johengen D; Luecke E; Rothrock G; McGowan I; van der Straten A; Desai T
Pharm Res; 2016 Jul; 33(7):1649-56. PubMed ID: 26975357
[TBL] [Abstract][Full Text] [Related]
15. Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques.
Gatto GJ; Krovi A; Li L; Massud I; Holder A; Gary J; Mills P; Mitchell J; Luecke E; Demkovich ZR; Heneine W; García-Lerma JG; Marzinke MA; Brand RM; Dobard CW; Johnson LM; Van Der Straten A
Front Pharmacol; 2022; 13():923954. PubMed ID: 35928266
[TBL] [Abstract][Full Text] [Related]
16. A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
Zane D; Roller S; Shelton J; Singh R; Jain R; Wang Y; Yang B; Felx M; Alessi T; Feldman PL
Microbiol Spectr; 2021 Sep; 9(1):e0033921. PubMed ID: 34190595
[TBL] [Abstract][Full Text] [Related]
17. Effects of Polymer Blending on the Performance of a Subcutaneous Biodegradable Implant for HIV Pre-Exposure Prophylaxis (PrEP).
Li L; Areson C; van der Straten A; Johnson LM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207212
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of a weekly transdermal delivery system of tenofovir alafenamide in hairless rats.
Jiang Y; Gao X; Singh ON; Zhang W; Agrahari V; Peet MM; Clark MR; Doncel GF; Banga AK
Int J Pharm; 2020 May; 582():119342. PubMed ID: 32315746
[TBL] [Abstract][Full Text] [Related]
19. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
[No Abstract] [Full Text] [Related]
20. Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP).
Li L; Johnson LM; Krovi SA; Demkovich ZR; van der Straten A
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33167509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
